Although there was a non-significant reduction in the number of hip fractures (9 on Tamoxifen, 20 on placebo) in the Tamoxifen group, the number of wrist fractures was similar in the two treatment groups (69 on Tamoxifen, 74 on placebo). A subgroup analysis of the P-1 trial, suggests a difference in effect in bone mineral density (BMD) related to menopausal status in patients receiving Tamoxifen. In postmenopausal women there was no evidence of bone loss of the lumbar spine and hip. Conversely, Tamoxifen citrate was associated with significant bone loss of the lumbar spine and hip in premenopausal women.
Tamoxifen Citrate is rarely administered to women with infertility due to ovaries dysfunction, ovulation disorders associated with high levels of estrogens preventing follicles from normal growth and maturation. It is prescribed on an individual scheme for every case. A doctor will never prescribe Tamoxifen without prior tests and examinations. To make a decision a patient needs Tamoxifen for treatment of infertility usually blood tests for hormones are done. A blood sample is taken on the second or third day of the menstrual cycle. Another symptoms of critical effect of high estrogen on the female health is a structure and thickness of endometrium during a menstrual cycle. Normally the endometrium grows adding about 1mm in two days. But the 14 th day of the cycle it reaches the thickness of 10-12mm and then the thickness is kept up to the end of the cycle. In the last days of the cycle the endometrium gets thinner.